Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms

Journal of Clinical Pathology

Volumn 63, Issue 10, 2010, Pages 942-946

  Chim, C S ^a   Wan, T S ^a   Fung, T K ^a   Wong, K F ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; JANUS KINASE 2;

ADULT; AGED; ARTICLE; BONE MARROW CANCER; CASITAS B LINEAGE GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; GENE INACTIVATION; GENE MUTATION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE TRANSFORMATION; MALE; MYELOFIBROSIS; ONCOGENE; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN METHYLATION; TET2 GENE; THROMBOCYTHEMIA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CCAAT-ENHANCER-BINDING PROTEINS; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEIN V-CBL; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIMARY MYELOFIBROSIS; PROTO-ONCOGENE PROTEINS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 77957824328     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.080218     Document Type: Article

References (14)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7. (Pubitemid 47281402)
2. Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 2005;165:2651-8.
3. Chim CS, Kwong YL, Chan PT, et al. Polycythemia vera in Chinese patients: thirty-six years of experience. Am J Hematol 1997;56:59-62.
4. Chim CS, Liang R, Kwong YL. Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol 2002;20:167-76. (Pubitemid 36070076)
5. Sanada M, Suzuki T, Shih LY, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009;460:904-8.
6. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301.
7. Chim CS, Wong AS, Kwong YL. Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia. Br J Haematol 2002;119:988-90.
8. Koschmieder S, Halmos B, Levantini E, et al. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 2009;27:619-28.
9. Porse BT, Bryder D, Theilgaard-Mönch K, et al. Loss of C/EBPa cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocytic lineage. J Exp Med 2005;202:85-96. (Pubitemid 41002912)
10. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-11.
11. Sábado Alvarez C. Molecular biology of retinoblastoma. Clin Transl Oncol 2008;10:389-94.
12. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144-7.
13. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009;113:6182-92.
14. Hackanson B, Bennett KL, Brena RM, et al. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res 2008;68:3142-51.